SchwartzGG: Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases. Cancer Epidemiol Biomarkers Prev, 2008; 17:478–483.
2.
RianchoJA, ArjonaR, ValleR, SanzJ, Gonzalez-MaciasJ: The clinical spectrum of hypocalcaemia associated with bone metastases. J Intern Med, 1989; 226:449–452.
3.
MurrayRMI, GrillV, CrinisN, HoPWM, DavisonJ, PittP: Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. J Clinic Endocrinol Metab, 2001; 86:4133–4138.
4.
ZuradelliM, MasciG, BiancofioreG, GulloG, ScorsettiM, NavarriaP, TancioniF, BerlusconiM, GiordanoL, SantoroA: High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid. Oncologist, 2009; 14:548–556.
